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Radical retropubic prostatectomy (RRP) is a well-established
treatment option for localized prostate cancer in patients less than
70 years of age. Unfortunately, in a proportion of these patients
postoperative prostate-specific antigen (PSA) does not reach
undetectable levels and biochemical relapse occurs (Pound et al,
1997; Graefen et al, 1999). Patients with organ-confined disease
are more likely to have prolonged biochemical disease-free
survival (BDFS). Consequently, presence of extracapsular disease
(pT3) or positive margins have been used not only to predict
outcome, but also to decide on adjuvant therapy (Partin et al, 1993;
D’Amico et al, 1998). However, this criterion is not reliable in
predicting biochemical relapse, and large numbers of patients (up
to 70%) with positive margins do not progress (Partin et al, 1998;
D’Amico et al, 1998). Moreover, patients with negative margins
are not guaranteed to be free from progression, approximately
10% progress in some series (Catalona and Smith, 1994; D’Amico
et al, 1998).
In an attempt to improve outcome from RRP, some have
attempted to select patients with a good prognosis. Probability
nomograms combining PSA levels, clinical stage and Gleason
score (so-called ‘Partin’s Tables’) have been advocated to predict
pathological stage, and by inference, risk of progression (Partin
et al, 1997). Although use of these tables has had the effect of
improving BDFS figures, they are not accurate enough to confi-
dently predict clinical or biochemical outcome for an individual
patient. Consequently, some patients with unfavourable risk
factors may be denied potentially curative treatment. Pre-operative
criteria other than Partin’s tables and postoperative criteria other
than surgical margins are needed to reliably predict biochemical or
clinical outcome.
PSA nadir measured with a sensitive assay offers the possibility
of confidently predicting the removal of all significant PSA
producing tissue within a few weeks of the operation. In contrast,
histological evidence of relapse is usually not attained with more
than 60% accuracy until the PSA rises above 2 ng ml–1 (Connolly
et al, 1996) which may not occur for many years after RRP. Thus,
the earliest indicator of prostate cancer relapse after radical prosta-
tectomy is a rising PSA. Most contemporary published series use a
PSA level > 0.2 ng ml–1 in defining undetectable levels of PSA
(Partin et al, 1999), but levels ranging from 0.1–4 ng ml–1 have
also been used (Frazier et al, 1993; Dillioglugil et al, 1995;
Feneley et al, 1996; Scardino, 1998). The advent and availability
of a sensitive PSA assay (Yu and Diamandis, 1993) raises ques-
tions regarding the appropriateness of these unvalidated levels.
Sensitive PSA assays have been reported as being clinically useful
(Yu et al, 1995) but their role in early detection and prediction of
biochemical relapses needs further assessment. Moreover, the
benefits of early detection of relapse are still unknown; early
detection of prostate cancer relapse might offer therapeutic advan-
tages. Indeed, a recent study suggests that salvage external beam
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radiotherapy (EBRT) to the prostate bed may be more effective if
given at low PSA levels (Egawa et al, 1999).
A reasonable hypothesis is that postoperative PSA nadir levels
measured by a sensitive PSA assay may provide useful prognostic
information and expedite decision-making regarding the use of
early salvage therapy. Thus, the objective of this study was to
evaluate the role of sensitive PSA assays following radical
prostatectomy.
PATIENTS AND METHODS
A consecutive series of 200 patients of mean age 61.2 years (range
43–73) were selected for RRP and simultaneous pelvic lymph
node dissection according to the following criteria. Patients had to
have clinically organ-confined disease with histological confirma-
tion of prostate cancer by transrectal ultrasound-guided needle
biopsy or transurethral resection of prostate (TURP). Isotope bone
scans were performed if the PSA was over 20 ng ml–1 or the
patient had musculoskeletal pain. All patients had a presumed life
expectancy in excess of 10 years, and no significant comorbidity.
Patients over the age of 70 years were only considered for RRP in
exceptional circumstances. Patients were not refused surgery
because of high biopsy Gleason scores or high pre-operative
serum PSA, providing they fulfilled the other criteria, and had
no evidence of extracapsular disease on CT scan or transrectal
ultrasound. 9 patients had pre-operative radiotherapy and were
excluded from subsequent analysis of biochemical disease-free
survival (BDFS). 12 patients had pre-operative hormone therapy.
Serum PSA levels were measured with the Roche COBAS®
CORE assay in the first 80 patients (lower detecting limit =
0.1 ng ml–1). From 1997 onwards, 120 patients had measurements
using the IMMULITE® ‘Third Generation’ sPSA assay
(Diagnostic Products Corporation, DPC, Gwynedd, UK). This
assay detects PSA down to below levels of 0.01 ng ml–1. Interassay
variation is negligible at ≥ 0.01 ng ml–1. This low detection level is
a consequence of the efficient centrifugal wash, which results in a
low non-specific signal accompanied by a large specific signal
afforded by the chemiluminescent label (Babson et al, 1991).
Mean pre-op PSA for the whole group was 13.3 ng ml–1 (range
0.18–59 ng ml–1, median 10 ng ml–1). (The patient with a pre-oper-
ative PSA of 0.18 ng/mL–1 had been previously treated by EBRT.)
Around half (48%) of patients had pre-op PSA levels of
>10 ng ml–1 (Table 1).
One surgeon between 1992–1999 performed all the operations
via the retropubic approach. When possible, a nerve-sparing
technique was used (Walsh et al, 1984). Two pathologists graded
the specimens using the Gleason classification system (Gleason,
1977). The new TNM staging system was used for clinical and
pathological staging. At initial biopsy, 31 (15.5%) patients had
Gleason grade 7 or above. Clinicopathological data is shown in
Table 1.
Patients were followed-up by PSA measurements every 3
months until a year and then every 6 months. Only 12 patients who
are still alive have not had a sensitive PSA measurement.
Biochemical relapse was defined as 3 consecutive rising PSA
values. PSA readings had to be at least 3 months apart. This is
consistent with the definition proposed by ASTRO (Cox, 1997).
An undetectable PSA nadir is defined as ≤ 0.01 ng ml–1.
The log rank test was used to analyse differences in survival
duration. Multivariate analysis of prognostic variables was
performed by the Cox proportional hazards model. In addition,
survival duration from the date of surgery to death from any cause
and survival free of biochemical relapse were estimated by the
Kaplan-Meier method.
Table 1 Pre and post-operative clinicopathological characteristics of 200 men with clinically localized prostate cancer
Number of patients (%)
Pre-operative criteria Pathological Stage Specimen Gleason Margins
T2 T3a T3b N1 2–4 5–6 7 8–10 Positive Negative Total
Biopsy Gleason
2–4 39 10 8 0 20 29 6 2 33 24 57 (28%)
5–6 68 23 21 2 9 65 28 10 68 44 112 (56%)
7 11 4 9 2 0 5 12 7 20 4 24 (12%)
8–10 0 3 4 0 0 1 3 3 6 1 7 (4%)
PSA (ng/ml)
<4 6 1 1 0 1 4 1 2 2 5 8 (4%)
4–10 71 18 7 0 17 52 17 10 53 43 96 (48%)
10.1–20 31 14 20 2 7 33 19 6 46 19 65 (32%)
>20 10 7 14 2 4 11 12 4 26 5 31 (16%)
Total 118 (59%) 40 (20%) 42 (21%) 4 (2%) 29 (14%) 100 (50%) 49 (25%) 22 (11%) 127 (63%) 73 (37%) 200 
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Figure 1 Kaplan-Meier biochemical disease-free survival curves for
patients with PSA nadir ≤ 0.01 ng ml–1 and PSA nadir >0.01 ng ml–1. 
Chi-square = 71.67, P < 0.0001RESULTS
Clinicopathological details are outlined in Table 1. 4 patients had
histopathologically proven nodal involvement, despite CT scans
showing normal pelvic lymph node morphology. 82 (41%) had
pT3 disease despite being considered clinically organ-confined. 49
(25%) had pathological specimen Gleason scores ≥ 7.
Median follow-up was 1.7 years (maximum 6.5 years). Overall
2-year survival was 98.3% (95% CI: 96.4–100%). 4 patients have
died, one of metastatic prostate cancer (5 years after RRP) and 3
from other causes. Overall prostate cancer specific survival was
100% at 2 years.
Patients who did not have evaluable nadirs. These included
those who had had prior radiotherapy (n = 9), early deaths (n = 3)
and adjuvant postoperative EBRT for positive margins (n = 4).
Another 44 patients had nadirs below the lower detection limit for
the Roche COBAS® CORE system. 13 patients have not yet
reached their nadir. PSA nadir data was therefore analysed in
134 patients. 73 patients achieved an undetectable PSA nadir
(≤ 0.01 ng ml–1). The median time to reach PSA nadir
≤ 0.01 ng ml–1 was 10.4 weeks (range 2.6–214 weeks).
Of the 200 patients, those who had pre-operative (n = 9) or
adjuvant EBRT (n = 4) or early deaths (n = 3) were excluded from
analysis of BDFS. Of the remaining 184 patients biochemical
relapse occurred in 72 (39%). Two-year BDFS was 68.2%
(61.5–75.9%).
Of the 134 patients with evaluable PSA nadir data recorded, 49
(36.5%) have failed biochemically. This gives a 2-year BDFS of
61.1% (95% CI: 51.6–70.6%). Out of the 73 patients who have
reached an undetectable nadir, only 2 have failed (3%); this
compares with 47 relapses out of the 61 patients (76%) who did
not reach undetectable levels. Patients who achieve undetectable
PSA nadir have significantly greater BDFS (Log Rank Test
P < 0.0001). The 2-year BDFS for PSA nadir >0.01 ng ml–1 was
26.4% (95% CI: 14.4–38.4%) compared to those with a PSA nadir
≤ 0.01 ng ml–1 of 94.8% (95% CI: 87.5–100%). Figure 1 shows
BDFS for nadir evaluable patients by comparing achievement of
undetectable PSA nadir.
Univariate analysis of variables predictive of BDFS showed no
significant association with age or biopsy Gleason score (Table 2).
However, seminal vesicle invasion (P=0.0013), surgical margins
(P=0.0004), specimen Gleason score (P=0.0002), extracapsular
spread (P ≤ 0.0001), pre-operative PSA (P < 0.0001) and unde-
tectable PSA nadir (P < 0.0001) were prognostic variables. All
these variables were entered into a Cox multivariate model to
determine which variables were of independent prognostic
significance. Table 3 shows that only undetectable PSA nadir
(P  ≤ 0.0001), positive surgical margins (P  = 0.03) and pre-
operative PSA (P = 0.04) were independent variables predicting
a favourable BDFS.
On the basis of the finding that PSA nadir is the most significant
predictor of BDFS, a model to predict PSA nadir and hence BDFS
was constructed using pre-operative variables to aid patient selec-
tion. The nomograms derived from the Charing Cross dataset is
shown in Table 4. Patients with low-grade tumours had a better
outcome. Moreover, the deleterious effect of increasing levels of
pre-op PSA level was less marked in well-differentiated tumours.
DISCUSSION
Radical retropubic prostatectomy is a popular treatment for men
less than 70 years with clinically localized prostate cancer. After
RRP, a proportion of patients will have pathological non-organ-
confined disease, often with positive margins. This has led to a
quest for accurate pre-operative markers with the aim of
increasing the identification of patients with organ-confined
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Table 2 Predictors of BDFS. Univariate analysis
Variable Chi P value
Squared
Age 0.001 0.97
Biopsy Gleason score 2.7 0.099
Seminal vesicle invasion 10.3 0.0013
Positive surgical margins 12.5 0.0004
Gleason of surgical specimen 14.1 0.0002
Extracapsular spread 16.9 <0.0001
Pre-operative PSA 18.4 <0.0001
PSA nadir ≤ 0.01 ng ml–1 71.6 <0.0001
Table 3 Predictors of BDFS. Multivariate analysis.
Variable Chi P value
square
Gleason specimen sum 3.551 0.0595
Pre-operative PSA 4.308 0.0379
Surgical margin positive 4.703 0.0301
PSA nadir ≤ 0.01 ng mL–1 26.910 <0.0001
Table 4 Probability tables enumerating the likelihood of reaching undetectable PSA (≤ 0.01 ng/ml) based on
pre-operative criteria; biopsy Gleason and PSA. Note that, in view of small numbers, Gleason 7 scores have
been included with poorly differentiated tumours graded 8–10.
Charing Cross tables:
numbers who achieved PSA nadir ≤ 0.01 ng/ml
Biopsy Gleason
PSA (ng/ml) 2–4 5–6 7–10 Totals
≤ 10 10/17 (59%) 33/46 (72%) 2/3 (66%) 45/66 (68%)
>10–20 11/18 (55%) 8/21 (38%) 3/9 (33%) 22/48 (46%)
>20 5/9 (55%) 1/9 (11%) 0/2 (0%) 6/20 (30%)
Totals 26/44 (59%) 42/76 (55%) 5/14 (36%) 73/134 (55%)Relapse-free survival after prostatectomy 1435
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disease. Patients with organ-confined disease are more likely to
have complete excision of the tumour, which should result in cure.
Thus, in previous large-scale studies of outcome after radical
prostatectomy, attention has largely focused upon histology of the
RRP specimen to define success of surgery. The overall incidence
of positive surgical margins after radical prostatectomy has been
reported to range from 7–45% in patients with clinically localized
cancer prior to surgery (Eggleston and Walsh, 1985; Catalona
and Bigg, 1990). The accuracy with which surgical margins can
predict outcome is reasonably good, especially if combined with
grade. Pound et al found that in men with capsular penetration
with Gleason score 2–6, the status of the surgical margin had a
significant effect on outcome at 10 years. However, the outcome in
both groups was good with the likelihood of an undetectable PSA
at 10 years with a negative margin being 89% and 72% for men
with a positive margin (Pound et al, 1997). Thus, biochemical
relapse is not always a consequence of positive surgical margins
(D’Amico et al, 1998). Opting for adjuvant therapy on the basis of
a positive surgical margin status alone may result in unnecessary
treatment of the patient.
This lack of reliability may be because of the heterogeneity of a
positive margin (Rosen et al, 1992). Positive apical margins are
apparently less clinically significant than positive posterior-lateral
margins (Fesseha et al, 1997). The pathological determination of
margin positive disease also requires its discrimination from
anatomical artefact, remembering that the prostate is in direct
contact with the rectum and pelvic sidewall with little or no
surrounding connective tissue elsewhere. Despite these limita-
tions, we identified positive margins as an independent predictor
of BDFS in our series.
Postoperative PSA readings are regarded by many to be the best
criteria for determining tumour-free status. However, levels less
than 0.2 ng ml–1 are generally considered of little clinical value,
despite some large clinical studies demonstrating early detection
of relapse with sensitive PSA assays (Yu et al, 1997). Indeed, the
most common level below which PSA is considered ‘unde-
tectable’ is 0.2 ng mL–1. In a recent study of the natural history of
PSA elevation following RRP, 23% of patients with ‘undetectable’
PSA (defined as less than 0.2 ng ml–1) biochemically relapsed
after 5 years (Pound et al, 1999). This suggests that PSA levels
<0.2 ng ml–1 are often associated with the presence of residual
prostate cancer.
In this study, sensitive PSA was used to measure nadir post
RRP. A level of greater than 0.01 ng ml–1 was found to be more
accurate than any other criteria for prediction of subsequent
biochemical relapse. Measuring the PSA to low levels minimizes
the risk of falsely reassuring patients of surgical cure. The most
sensitive PSA assay ever reported was by Ferguson et al (1996).
Such ultrasensitive assays which detect PSA to levels less than
0.01 ng ml–1 may subsequently be shown to be even more accurate
in predicting biochemical outcome.
It is not possible to exclude some of the difference on BDFS
accounted for by prolonged lag time in patients who achieve unde-
tectable nadirs. However, the contour of the BDFS Kaplan-Meier
Curve (Figure 1) for patients with undetectable nadir suggests that
a plateau is achieved after 2 years. It is anticipated that prolonged
follow-up of this series of patients will confirm this.
In addition sensitive PSA assays can detect disease relapse by
consecutive PSA rises from very low levels (Witherspoon, 1997).
Concern regarding the use of sensitive assays in this way is the
potential lack of specificity in diagnosing prostate cancer recur-
rence. This anxiety relates to the fact that extraprostatic sources of
PSA production are known to exist (Kamoshida and Tsutsumi,
1990; Yu et al, 1995). Nevertheless, this is a very small contribu-
tion to serum PSA (Oesterling et al, 1996) and is believed not to
complicate the interpretation of monitoring since these sources
contribute a stable amount of PSA in the serum, which does not
change with time. Similarly, although PSA values rise as part of
the natural history in benign as well as malignant prostatic disease,
this has only been reported in patients with the prostate in-situ.
For example, patients with benign prostatic hyperplasia typically
have a PSA rise of 0.2 ng ml–1 year–1 (Collins et al, 1993). It is not
necessarily the case that residual benign prostatic tissue after RRP
will have the similar PSA kinetics. Recent papers have suggested
the use of PSA doubling time to predict malignant potential (Patel
et al, 1997), but even this parameter is of questionable value. Our
data suggest that all patients who relapse biochemically continue
to have an unremitting rise, and this occurs whether biochemical
relapse is detected early (with sensitive assays) or late.
Another reason for the limited enthusiasm for sensitive assays is
the lack of proven benefit from the use of early salvage external
beam radiotherapy (EBRT). Critics claim that salvage EBRT to the
prostate bed risks over-treating patients with rising PSA due to
either undiagnosed metastatic disease or benign disease. However,
potential benefits do exist for salvage EBRT. In a recent study
investigating the outcomes of patients who received salvage EBRT
after radical retropubic prostatectomy, 40% of the 32 patients
enrolled had ‘undetectable’ post-radiotherapy PSA values at an
average follow-up of 12 months. Moreover, the best outcomes
were associated with patients who had the lowest pretreatment
PSA levels (Egawa et al, 1999).
Probability tables as shown in this paper provide information on
the likelihood of achieving an undetectable PSA nadir based on
pre-op PSA and biopsy Gleason score. Although this is useful, the
ability to predict accurately biochemical outcome in an individual
patient prior to surgery is still unattainable. Reliably selecting
patients for RRP who will not relapse biochemically after surgery
continues to be a problem. However, ultrasensitive PSA assays are
of benefit in the postoperative detection of relapse which is now
known to be advantageous in planning adjuvant therapy.
CONCLUSIONS
The role of RRP has been controversial in the UK partly because
of the scepticism regarding the effectiveness of the procedure.
Undoubtedly, not all patients undergoing RRP are cured of
prostate cancer and patient selection is an important factor.
Patients are keen to know if they have been cured of cancer after
RRP. Until recently, to predict this we have been reliant upon
histology alone. However, ultrasensitive PSA assays now enable
us more accurately to advise patients of their chance of PSA
relapse within 2 months of surgery and appears to be a reliable
predictor of cure of prostate cancer.
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